Ovarian cancer (QS18)
Fast, easy summary view of NICE guidance on 'ovarian cancer'
This NICE quality standard defines clinical best practice within this topic area. It provides specific, concise quality statements, measures and audience descriptors to provide the public, health and social care professionals, commissioners and service providers with definitions of high-quality care.
This quality standard covers the recognition and initial management of ovarian cancer.
- NICE clinical guideline: CG122 Ovarian cancer
- NICE technology appraisal: TA222 Ovarian cancer (relapsed) - trabectedin
- NICE technology appraisal: TA91 Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review)
- NICE technology appraisal: TA55 Ovarian cancer - paclitaxel (review)
- The Royal College of Radiologists (2012). iRefer: Making the best use of clinical radiology - referral guidelines.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: ovarian cancer
This page was last updated: 15 April 2013
Quality standard formats
Information for the public
Implementation tools and resources
The summary of the statements in the quality standard written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Full quality standard
The published full quality standard for health and social care professionals, public health practitioners, commissioners, service providers and patients, carers and the public, with quality measures, outcomes definitions and data sources.
Many organisations share NICE's commitment to improve quality by making it clear what quality care is for patients and the public, health and social care professionals, commissioners and service providers.
So that these standards reach the widest possible audience, some of these organisations have endorsed the ovarian cancer quality standard.
These organisations are: